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Purpose. Flavopiridol is a potent cyclin-dependent kinase (CDK) inhibitor that has preclinical activity in many tumours. This
synthetic ﬂavonoid was tested in a phase II nonrandomized, nonblinded multicentre clinical trial to determine its activity and
toxicity in patients with previously untreated metastatic or locally advanced soft tissue sarcoma. Methods. A total of 18 patients
with histologically conﬁrmed nonoperable soft tissue was treated with ﬂavopiridol administered at a dose of 50 mg/m2 IV over 1
hour daily
￿3d a y se v e r y3w e e k s .Results. Eighteen patients were accrued to the study over a period of 6 months. No objective
responses were noted in the seventeen evaluable patients. Eight patients (47%) exhibited stable disease after 2 cycles (median
duration of 4.3 months (range 1.4–6.9 months). Kaplan-Meier estimates for 3- and 6-month progression-free survivial rates were
44 percent and 22 percent, respectively. The only grade 3 toxicities were diarrhea (N = 2), nausea (N = 2), gastritis (N = 1),
and fatigue (N = 1). Ninety-four percent of patients received
￿ 90% of the planned dose intensity, during 55 treatment cycles.
Conclusions. Flavopiridol was well tolerated at the dose and schedule used in this study, however, no objective treatment responses
were seen and thus our results do not support further exploration of ﬂavopiridol as a monotherapy at this dose and schedule in
soft tissue sarcomas.
Copyright © 2006 Don G. Morris et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Soft tissue sarcomas (STS) constitute a heterogenous group
of cancers that all share origins from mesenchymal tissue.
The annual incidence of STS is approximately 9420 cases
per year in the United States, resulting in 3490 deaths per
year and represents approximately 1% of all adult malignan-
cies [1]. Even with current advances in treatment, mortality
rates still approach 50 percent for newly diagnosed patients.
Current treatments for nonoperable or metastatic STS re-
main unsatisfactory. Although, there are multiple drugs that
have modest eﬃcacy in treating STS, the single most eﬀective
drugisdoxorubicin(75mg/m2)withresponseratesgenerally
less than 25% in recent studies [2]. The use of combination
chemotherapy, particularly ifosfamide/doxorubicin-based
regimens, has increased response rates, however, there is
still no signiﬁcant improvement in survival and signiﬁcantly
increased toxicity has been found [3, 4]. Further, despite
promising results in phase II studies, randomized phase III
trials evaluating dose escalation of doxorubicin/ifosfamide-
based regimes supported by growth factors have not shown
as u r v i v a lb e n e ﬁ t[ 5, 6]. Given these poor results, there has
been a trend towards the use of single agent chemotherapy in
patients receiving palliative treatment.
Newer agents with diﬀerent/novel mechanisms of action
aredesperatelyneeded.Preclinicalinvestigationsintotherole
of cyclins and cyclin-dependent kinases (CDKs) in sarcoma
indicate that many STSs acquire changes that disrupt check-
point control (ie, CDK overexpression) resulting in unregu-
latedprogressionthroughthecellcycle.Alterationsintheex-
pression of cyclins D1,2,3, E,a n dA and the CDK inhibitors,
p21andp27haveallbeenshowntobemarkersofpoorprog-
nosis in many STS [7–10].
Flavopiridol, an N-methylpiperidinyl, chlorophenyl ﬂa-
vone, is an analogue of a naturally occurring ﬂavonoid iso-
lated from the bark of Dysoxylum binectariferum,ap l a n t2 Sarcoma
indigenous to India. It was the ﬁrst potent CDK inhibitor
to enter human clinical trials and inhibits the kinase activ-
ity of multiple CDKs with CDK 1,2,4 and 7 IC50s in the
100–400nM range. It also interferes with the phosphoryla-
tion events necessary to activate CDKs and has been shown
to downregulate transcription of the cyclin D1 gene [11]a n d
vascularendothelialgrowthfactorexpression[12].Flavopiri-
dol xenograft model systems in nonsmall cell lung, breast,
prostate,andseveralothertumourshaveshowncytotoxicac-
tivity [13, 14]. Several phase I clinical trials have established
dose schedules that are well tolerated and achieve serum lev-
els adequate for CDK inhibition. Published phase II studies
in renal [15], gastric [16], nonsmall cell lung [17], and head
a n dn e c k[ 18] cancers have used a continuous infusional
schedule, however, in xenograft models, peak concentrations
achieved in a bolus schedule correlated best with antitumour
activity [19]. A phase I trial using a bolus, daily
￿3s c h e d -
ule in advanced neoplasms was associated with stabilization
of disease in the setting of progressive disease prior to entry
onto the trial [20]. A recent phase II study using ﬂavopiridol
(50mg/m2) IV bolus daily
￿3 in advanced renal cell carci-
noma revealed an acceptable toxicity proﬁle, an overall re-
sponse rate of 12% and a stable disease rate of 41% [21].
Due to the ease of administration, evidence of clinical ac-
tivity in other histologies and phase I/II experience, the daily
￿3 schedule was adopted in this current study.
METHODS
Patienteligibility
Patientswithdocumentedmetastaticorlocallyadvancedsoft
tissue sarcoma, not curable by other means, were eligible
for this trial. Eligibility criteria were as follows: histologically
documented soft tissue sarcoma; presence of at least one site
of unidimensionally measurable clinically and/or radiolog-
ically documented disease; age
￿ 18 years, life expectancy
of at least 12 weeks; Eastern Cooperative Oncology Group
performance status
￿ 2; and no prior systemic therapy for
metastaticdisease.Prioradjuvantchemotherapywaspermit-
t e da sl o n ga st r e a t m e n th a db e e nc o m p l e t e d
￿ 6 months
since the last dose of therapy. Patients could not have re-
ceived radiotherapy to the sole site of measurable disease un-
less it was a current site of progressive disease, and no more
than 25% of functioning bone marrow could have been ir-
radiated. Previous surgery was allowed if
￿ 4 weeks prior to
initiating treatment. Laboratory requirements included the
following: absolute granulocyte count
￿ 1.5
￿109/L; platelet
count
￿ 100
￿109/L;AST
￿ 2.5
￿uppernormallimit(UNL);
serum creatinine
￿ UNL; bilirubin
￿ UNL. All patients must
have given informed consent according to the requirements
of their local Institutional and/or University Human Experi-
mentation Committee.
Treatment
Flavopiridol (Aventis Pharmaceuticals, Inc) was supplied by
theCancerTherapyEvaluationProgram(CTEP),Divisionof
Cancer Treatment and Diagnosis, National Cancer Institute,
Bethesda, Md, USA. The ﬂavopiridol was supplied as a sterile
10mg/ml solution in vials of 50mg of free base equivalent.
The individually calculated dose was diluted prior to infu-
sion with 0.9% sodium chloride injection USP or 5% dex-
troseinjectionUSPtoﬁnalconcentrationsrangingfrom0.09
to 0.5mg/ml ﬂavopiridol.
Flavopiridol was administered in the outpatient setting
as a 1 hour infusion at a dose of 50mg/m2 daily
￿3d a y s
every 21 days. Vital signs were monitored every 30 minutes
￿5 beginning at the start of infusion until 1 hour post infu-
sion. Antidiarrheal prophylaxis and antiemetic prophylaxis
were prescribed as follows: 4 chewable Pepto Bismol tablets
1 hour before ﬁrst dose of ﬂavopiridol, then 2 tablets every 6
hoursuntil12hoursafterthelastdoseofﬂavopiridol(day3),
ondansetron 8mg orally every 12 hours beginning 12 hours
before treatment and continuing until 12 hours after the last
dose of ﬂavopiridol (day 3). Loperamide was started if di-
arrhea occurred, using a dose regimen of 2mg orally q.2h
while awake and q.4h during sleep until 12h diarrhea-free.
Dose reductions were allowed (dose level: 1 = 37.5mg/m 2/d,
dose level: 2 = 28mg/m2/d), if the following toxicities were
seen: diarrhea
￿ grade 3 associated with mucus or dehy-
dration; nausea and vomiting
￿ grade 3 despite antiemet-
ics; granulocyte nadir < 0.5
￿109/L and/or neutropenia with
fever or infection; platelet nadir < 25
￿ 109/L and/or throm-
bocytopenic bleeding; or any nonhematologic toxicity (ex-
cept alopecia)
￿ grade 3. Patients requiring more than two
dose reductions were removed from protocol treatment.
Treatment continued until progression, or for 2 cycles af-
ter complete or stable partial response. Nonresponding sta-
ble patients continued on treatment until progression, or al-
ternatively could be removed from therapy after 6 cycles at
the investigator’s discretion. After termination from proto-
col treatment, all patients were seen at 4 weeks, then every 3
months until progression or death.
Responseandtoxicityassessment
Patients were considered evaluable for response if they had
received at least 1 cycle of therapy and had their disease
reevaluated. Patients were evaluated for response every 6
weeks (every 2 cycles) using the same investigations that
demonstrated measurable disease at baseline. Response and
progression were evaluated using the RECIST criteria (re-
sponse evaluation criteria in solid tumors) [22].
Patients were considered evaluable for toxicity after their
ﬁrst infusion of ﬂavopiridol. A history and physical exami-
nation were performed on day 1 of each cycle with an assess-
mentoftoxicityduringtheprevioustreatmentinterval.CBC,
platelets, diﬀerential, bilirubin and AST were performed on
days 1, 8, and 15, and BUN, creatinine, electrolytes, LDH,
fasting glucose, and alkaline phosphatase were performed on
day 1 of each cycle. Toxicities were graded according to the
NCI Common Toxicity Criteria Version 2.0[ 23].
Statisticalanalysis
The primary endpoint of this phase II study was objective
response rate, with secondary endpoints of toxicity, time toDon G. Morris et al 3
Table 1: Patient characteristics (n = 18 patients).
Number of patients
Patients entered on study 18
Evaluable for toxicity 18
Evaluable for response 17
Median age (range) 52(36–79)
Gender
Female 6
Male 12
Performance status
07
19
22
Prior therapy
Adjuvant chemotherapy 3
Adjuvant immunotherapy 1
Radiotherapy 10
Number of Prior chemo regimens
01 5
13
Sites of disease
Abdomen 1
Adrenal 1
Bone 3
Chest wall 1
Kidney 1
Liver 5
Lung 13
Bone marrow 1
Nodes 4
Pelvis 3
Pleural eﬀusion 1
Pleura 1
Retroperitoneal 2
Subcutaneous soft tissue 5
Number of sites of disease
14
26
37
￿ 41
Stage IV disease 18
progression, early progression rate, and response duration.
Inordertominimizetheexpectednumberofpatientstreated
intheeventthattheregimenprovedtobeverydisappointing
or very successful, a two-stage design was used for patient
accrual. This design tests the null hypothesis (H0) that the
true response rate is < 5% versus the alternative hypothesis
(HA) that the true response rate is > 20%. The signiﬁcance
level (ie, the probability of rejecting H0 when it is true) is
0.058. The power is 0.865 when the true response probability
is 20%. If there were no responses after the ﬁrst 15 patients,
the response rate is concluded to be < 5% and accrual was to
be stopped. If there were one or more responses, accrual was
to continue to 30 evaluable patients.
Table 2: Histology (n = 18 patients).
Number of patients
Histology
Angiosarcoma 2
Clear cell 1
Epithelial sarcoma 1
Fibrosarcoma 1
GI stromal cell 2
Malignant hemangiopericytoma 1
Leiomyosarcoma 2
Liposarcoma 2
Malignant ﬁbrous histiocytoma 1
Malignant schwannoma 1
Synovial sarcoma 1
Sarcoma NOS 3
RESULTS
Patientcharacteristics
A total of 18 patients were accrued onto this study. All pa-
tients were evaluable for toxicity and 17 patients were evalu-
able for response (1 patient discontinued protocol without
disease assessment). The characteristics of the patients are
outlined in Table 1. Four patients had received treatment in
the adjuvant setting (3 chemotherapy, 1 immunotherapy)
and 10 had received radiation therapy prior to entry onto
the trial. All patients were stage IV at the time of entry onto
the trial. The most common sites of metastatic disease were
pulmonary (13/18), hepatic (5/18) and subcutaneous (5/18).
T h eh i s t o l o g i c a ls u b t y p e sa r el i s t e di nTable 2.
Overall, ﬂavopiridol was well tolerated with 17/18 pa-
tients receiving the planned dose intensity. One patient had
ap r o t o c o lm a n d a t e dd o s er e d u c t i o nd u et og r a d e4n e u -
tropenia (a second patient who experienced grade 4 neu-
tropenia failed to receive the dose reduction). Two doses
delays occurred during the trial, both nontoxicity related.
The toxicities reported to be possibly related to the protocol
treatment are outlined in Table 3. The most common toxic-
ities included diarrhea (83%), nausea (67%), fatigue (61%),
anorexia (50%), and vomiting (39%). The toxicities were
generally grade 1 or 2, although two patients experienced
grade 3 diarrhea and one patient was hospitalized for gastri-
tis while neutropenic. Three patients experienced grade 3/4
leucopenia and 6 patients with grade 3/4 granulocytopenia
(see Table 4). The median time to leukocyte and granulo-
cyte nadir was 8-9 days. Biochemical toxicities (see Table 5)
were generally mild with one patient exhibiting grade 2 total
bilirubin and alkaline phosphatase elevations.
Treatmentandresponse
Ninety-four percent of patients received
￿ 90% of planned
dose intensity. A total of 55 cycles of treatment were given.
The median number of treatment cycles was 3 (range 1–64 Sarcoma
Table 3: Treatment-related
￿ nonhematologic toxicities (worst by patient) (n = 18 patients).
Grade
￿
￿
Toxicity 1 2 3 4 5 Total %pts
Flu-like symptoms
Fever 1 — — — — 1 (5.6)
Fatigue 5 5 1 — — 11 (61.1)
Rigors, chills 4 — — — — 4 (22.2)
Gastrointestinal
Anorexia 6 3 — — — 9 (50.0)
Constipation — 2 — — — 2 (11.1)
Diarrhea 7 6 2 — — 15 (83.3)
Dysphagia 2 — — — — 2 (11.1)
Mouth dryness 1 — — — — 1 (5.6)
Gastritis — — 1 — — 1 (5.6)
Nausea 6 4 2 — — 12 (66.7)
Salivary gland changes 2 — — — — 2 (11.1)
Stomatitis 1 — — — — 1 (5.6)
Taste disturbance 6 — — — — 6 (33.3)
Vomiting 4 3 — — — 7 (38.9)
Hemorrhage
Melena/GI bleeding 1 — — — — 1 (5.6)
Hematuria — 1 — — — 1 (5.6)
Infection
Infection w/o neutropen — 1 — — — 1 (5.6)
Pain
Abdominal pain 1 1 — — — 2 (11.1)
Headache 1 1 — — — 2 (11.1)
Myalgia 2 — — — — 2 (11.1)
Dermatology
Alopecia 3 — — — — 3 (16.7)
Dry skin — 1 — — — 1 (5.6)
Injection site reaction 1 — — — — 1 (5.6)
Rash/desquamation 1 — — — — 1 (5.6)
Any 17 14 6 0 0 18 (100.0)
￿Considered by investigator to be “possibly” or “deﬁnitely” related to protocol treatment.
￿
￿Toxicity graded according to NCI Common Toxicity Criteria Version 2.0.
Table 4: Treatment-related hematologic toxicity (worst by patient).
No of evaluable
￿ patients Grade
￿
￿
—0 1 2 3 4
Granulocytes 18 6 2 4 4 2
Hemoglobin 18 7 8 2 1 —
P l a t e l e t s 1 8 1 44———
WBC 18 8 4 3 2 1
￿Includes patients with at least one evaluable cycle (blood count done
between days 7–16).
￿
￿Toxicity graded according to NCI Common Toxicity Criteria Version 2.0.
cycles). One patient had a dose reduction due to treatment
toxicity, and 2 patients had dose delays due to nontreatment
related factors. Of the 18 patients entered onto the study, 14
patients were removed from the study for progressive disease
(4/14 symptomatic progression). There was one tumour re-
lated death. Of the three remaining patients one completed
the study and a further two patients were removed from the
study upon the advice of their physician.
The rates of complete and partial response, stable disease
and progressive disease are given in Table 6. Of the seventeen
patients evaluable for response (one patient discontinued
treatment without tumour assessment), there were no doc-
umented complete or partial responses (overall response rate
= 0.0%, 95% CI: 0.0–16.2%). As per the two-stage design of
the study, accrual was thus discontinued after the initial co-
hort of patients was enrolled. Stable disease for more than
2 cycles was documented in eight patients (47%) all with
diﬀerent histologies, with a median duration of 4.3 monthsDon G. Morris et al 5
Table 5: Treatment-related biochemical toxicity (worst by pa-
tient)
￿.
Toxicity No of evaluable
￿
Grade
￿
￿
patients
— 01234
Creatinine 18 17 1 — — —
SGOT (AST) 15 17 3 — — —
Bilirubin
All patients 16 15 — 1 — —
Normal baseline 15 14 — 1 — —
Alkaline phosphatase
All patients 15 13 1 1 — —
Normal baseline 14 13 1 — — —
Hyperglycemia
All patients 13 8 5 — — —
Normal baseline 8 6 2 — — —
￿Indicates patients with at least one blood sample taken after day 1.
￿
￿Toxicity graded according to the NCI Common Toxicity Criteria Version
2.0.
Table 6: Conﬁrmed response (n = 17 evaluable patients). Overall
response rate—0.0% (95% CI: 0.0–16.2%).
Duration (months)
No patients Median Range
Complete response (CR) 0 — —
Partial response (PR) 0 — —
Stable disease (SD) 8 4.3 1.4–6.9
Progressive disease (PD) 9 — —
(range1.4–6.9 months). Interesting, estimates ofprogression
free survival at 3 months and 6 months were 44% and 22%,
respectively suggestive of possible disease stabilization.
DISCUSSION
Flavopiridol was the ﬁrst example of a cyclin-dependent ki-
nase inhibitor to be tested in clinical trials. Although it ex-
hibits a relative selectivity for CDKs, it also has been re-
ported to inhibit protein kinase C at an IC50 of 6umol/L,
cyclic adenosine triphosphate-dependent kinase and epi-
dermal growth factor-receptor kinase at IC50s of 145 and
25umol/L, respectively [24]. Flavopiridol has also been re-
ported to suppress the transcription of cell-cycle speciﬁc
genes, including cyclin D1 and induce apoptosis in pre-
clinical models at micromolar concentrations [11, 13, 25–
27]. Multiple phase I and II trials have investigated the
dose/schedule, toxicity and eﬃcacy of ﬂavopiridol. Tan et
al reported on a phase I trial of a daily 1 hour infusion sched-
ule that achieved the minimal inhibitory concentrations (>
3umol) that inhibited CDKs in vitro [20]. There was a sug-
gestion from this study that the toxicity proﬁle found with
the72hourinfusionschedulewasalteredwithbolusschedul-
ing, that is, decreased thrombotic and asthenic complica-
tions and increased diarrhea/myelosuppression that corre-
lates with peak plasma concentrations, consistent with our
study.
This study demonstrates that ﬂavopiridol can be given
safely in an outpatient setting using a bolus dose schedule.
Expected toxicities of diarrhea, nausea, and vomiting were
manageable as long as patients received adequate prophylac-
tic treatment. Of the 18 patients enrolled on the study, only
one patient required a dose reduction. Hematologic toxicity
was modest.
Although there were no objective complete or partial re-
sponses seen in our patient population, 47% of evaluable pa-
tients experienced stable disease for at least 2 cycles, the ma-
jority of whom had progressive disease at study entry.
Despite the potential for activity in STS, no objective
responses were seen. It has been postulated that ﬂavopiri-
dol may act as a modulator of cytotoxic chemotherapeu-
tic agents, such as mitomycin C in gastric cancer, the tax-
anes, anthracyclines, gemcitabine in breast cancer and ara-c
in acute leukemias [25, 28–30].
Resistance to ﬂavopiridol associated with overexpression
of ATP-binding proteins and cyclin E has been described in
breast and colon cancer cell lines, respectively [31, 32]. There
has also been a report of an interaction between ﬂavopiridol
and MRPI, suggesting a potential drug resistance plenotype
[33].
In some recent clinical trials, stable disease has been
added to objective response and termed “clinical beneﬁt re-
sponse” [34]. This study was not designed to assess “clinical
beneﬁt response” or to address the possibility of cytostatic
mechanismsofaction;thereforeaccrualwasdiscontinuedaf-
ter no responses were seen in the ﬁrst seventeen evaluable
patients, as required by the statistical design of the study. An
assessment of “clinical beneﬁt response” may be an impor-
tant component in the design of future studies particularly
for agents that are postulated to be cytostatic in action. Fur-
ther, Van Glabbeke et al have suggested that 6 month pro-
gression free survival rates of > 30% in phase II trials may
provide evidence of activity in ﬁrst line soft tissue sarcoma to
carry agents into phase III trials [35]. Our results of 3 month
and 6 month PFS rates of 44% and 22%, respectively, how-
ever, do not compare favorably to these numbers. If there is
a role of ﬂavopiridol in STS as a treatment modality, it may
well be in the setting of combination with conventional cyto-
toxic chemotherapy.
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